2. Achour A., Kacem M., Dibej K., et al.. One year course of oral sulodexide in the management of diabetic nephropathy. J Nephrol. 2005;18(5):568–74.

3. Ravera M., Re M., Weiss U., et al. Emerging therapeutic strategies in diabetic nephropathy. J Nephrology. 2007;20(12):23–32.

4. Reidy K., Kang H.M., Hostetter T., Susztak K. Molecular mechanisms of diabetic kidney disease. J Clin Invest. 2014;124(6):2333–40. Doi: 10.1172/JCI72271.

5. Toth-Manikowski S., Atta M.G. Diabetic kidney disease: pathophysiology and therapeutic targets. J Diabetes Res. 2015;2015:697010. Doi: 10.1155/2015/697010.

6. Valocikova I. Sulodexid and nephrotic syndrome in patients with diabetic nephropathy. Vnitr Lek. 2011;57(5):507–10.

7. Шестакова М.В., Чугунова Л.A., Воронцов A.В., Дедов И.И. Эффективность Сулодексида – низкомолекулярного гепарина – в терапии диабетической нефропатии. Терапевтический Архив. 1997;69(6):34–7.

8. Lauver D.A., Lucchesi B.R. Sulodexide: a renewed interest in this glycosaminoglycan. Cardiovasc Drug Rev. 2006;24(3–4):214–26. doi: 10.1111/j.1527-3466.2006.00214.x.

9. Reeves W.B., Rawal B.B., Abdel-Rahman E.M., Awad A.S. Therapeutic modalities in diabetic nephropathy: future approaches. Open J Nephrol. 2012;2(2):5–18. Doi: 10.4236/ojneph.2012.22002.

10. Залевская А.Г., Астамирова Х.С., Карпова И.А., Попова С.Г. Испытание низкомолекулярного гепарина сулодексида в терапии диабетической нефропатии. Терапевтический Архив. 1998;70(3):71–4.

11. Skrha J., Perusicova J., Kvasnicka J., Hilgertová J. The effect of glycosaminoglycan sulodexide on oxidative stress and fibrinolysis in diabetes mellitus. Sb Lek. 1998;99(2):103–9.

12. Lewis E.J., Lewis J.B., Greene T., et al. Collaborative Study Group Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis. 2011;58(5):729–36. Doi: 10.1053/j.ajkd.2011.06.020.

13. Packham D.K., Wolfe R., Reutens A.T., et al. Collaborative Study Group Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol. 2012;23(1):123–30. Doi: 10.1681/ASN.2011040378.

14. Kunz R., Friedrich C., Wolbers M., Mann J.F. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148(1):30–48. Doi: 10.7326/0003-4819-148-1-200801010-00190.

15. Friedrich J.O., Adhikari N., Herridge M.S., Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med. 2005;142(7):510–24. Doi: 10.7326/0003-4819-142-7-200504050-00010.

16. Poplawska A., Szelachowska M., Topolska J., et al. Effect of glycosaminoglycans on urinary albumin excretion in insulin-dependent diabetic patients with micro- or macroalbuminuria. Diabetes Res Clin Pract. 1997;38(2):109–14. Doi: 10.1016/s0168-8227(97)00096-x.

17. Skrha J., Perusicova J., Pont’uch P., Oksa A. Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients. Diabetes Res Clin Pract. 1997;38(1):25–31. doi: 10.1016/s0168-8227(97)00076-4.

18. Blouza S., Dakhli S., Abid H., et al. DAVET (Diabetic Albuminuria Vessel Tunisia Study Investigators) Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy. J Nephrol. 2010;23(4):415–24.

19. Дедов И.И., Шестакова М.В., Воронцов А.В., Палаццини Е. Рандомизированное контролируемое исследование терапии сулодексидом для лечения диабетической нефропатии. Nephrol Dial Transplant. 1997;12(11):2295–300.

20. Sulikowska B., Olejniczak H., Muszyńska M., et al. Effect of sulodexide on albuminuria, NAG excretion and glomerular filtration response to dopamine in diabetic patients. Am J Nephrol. 2006;26(6):621–28. Doi: 10.1159/000098195.

21. Kang Z. Study on effect of Sulodexide in treatment of diabetic nephropathy stage III. Guide of China Medicine. 2013;11:25–8.

22. Heerspink H.L., Greene T., Lewis J.B., et al. Collaborative Study Group Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant. 2008;23(6):1946–54. Doi: 10.1093/ndt/gfm893.

23. Gambaro G., Kinalska I., Oksa A., et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol. 2002;13(6):1615–25. Doi: 10.1097/01.asn.0000014254.87188.e5.

24. Gambaro G. Discounting the efficacy of sulodexide in diabetic nephropathy is premature. Am J Kidney Dis. 2012;60(1):169–70. Doi: 10.1053/j.ajkd.2012.01.029.

25. Wilson T.W. Dealing with Paucity of Data in Meta-Analysis of Binary Outcomes

26. Friedrich J.O., Adhikari N.K., Beyene J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol. 2007;7:5. Doi: 10.1186/1471-2288-7-5.

27. Radbill B., Murphy B., LeRoith D. Rationale and strategies for early detection and management of diabetic kidney disease. Mayo Clin Proc. 2008;83(12):1373–81. Doi: 10.1016/S0025-6196(11)60786-6.

28. Rossing P. Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr Diab Rep. 2006;6(6):479–83. Doi: 10.1007/s11892-006-0083-y.

29. Sarafidis P.A., Khosla N., Bakris G.L. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007;49(1):12–26. Doi: 10.1053/j.ajkd.2006.10.014.

30. Khosla N., Bakris G. Lessons learned from recent hypertension trials about kidney disease. Clin J Am Soc Nephrol. 2006;1(2):229–235. Doi: 10.2215/CJN.00840805.

31. Ziyadeh F.N., Sharma K. Overview: combating diabetic nephropathy. J Am Soc Nephrol. 2003;14(5):1355–57. Doi: 10.1097/01.asn.0000065608.37756.58.

32. Adler S.G., Schwartz S., Williams M.E., et al. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol. 2010;5(8):1420–28. Doi: 10.2215/CJN.09321209.

33. Miner J.H. Glomerular filtration: the charge debate charges ahead. Kidney Int. 2008;74(3):259–61. Doi: 10.1038/ki.2008.260.

34. Gaddi A.V., Cicero A.F., Gambaro G. Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered. Int J Nephrol Renovasc Dis. 2010;3:99–105. Doi: 10.2147/ijnrd.s5943.

35. Parthasarathy N., Spiro R.G. Effect of diabetes on the glycosaminoglycan component of the human glomerular basement membrane. Diabetes. 1982;31(8 Pt 1):738–41. Doi: 10.2337/diab.31.8.738.

36. Tanios B.Y., Ziyadeh F.N. Emerging therapies for diabetic nephropathy patients: beyond blockade of the reninangiotensin system. Nephron Extra. 2012;2(1):278–82. Doi: 10.1159/000343312.

37. Shimomura H., Spiro R.G. Studies on macromolecular components of human glomerular basement membrane and alterations in diabetes. Decreased levels of heparan sulfate proteoglycan and laminin. Diabetes. 1987;36(3):374–81. Doi: 10.2337/diab.36.3.374.

38. Solini A., Vergnani L., Ricci F., Crepaldi G. Glycosaminoglycans delay the progression of nephropathy in NIDDM. Diabetes Care. 1997;20(5):819–23. Doi: 10.2337/diacare.20.5.819.

39. Masola V., Zaza G., Gambaro G. Sulodexide and glycosaminoglycans in the progression of renal disease. Nephrol Dial Transplant. 2014;29(suppl 1):74–9. Doi: 10.1093/ndt/gft389.

40. Weiss R., Niecestro R., Raz I. The role of sulodexide in the treatment of diabetic nephropathy. Drugs. 2007;67(18):2681–96. Doi: 10.2165/00003495-200767180-00004.

41. Abaterusso C., Gambaro G. The role of glycosaminoglycans and sulodexide in the treatment of diabetic nephropathy. Treat Endocrinol. 2006;5(4):211–22. Doi: 10.2165/00024677-200605040-00002.

42. Wijnhoven T., Lensen J.F., Rops A.L., et al. Antiproteinuric effects of glycosaminoglycan-based drugs. Curr Opin Mol Ther. 2007;9(4):364–77.

43. House A.A., Weir M.A. Sulodexide for diabetic nephropathy: another one bites the dust. Am J Kidney Dis. 2011;58(5):692–94. Doi: 10.1053/j.ajkd.2011.08.011.

44. Coccheri S. Game not over for sulodexide. Am J Kidney Dis. 2012;59(3):467. Doi: 10.1053/j.ajkd.2011.12.010.

45. Yung S., Chau M.K., Zhang Q., et al. Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin-induced type I diabetic nephropathy. PLoS One. 2013;8(1):e54501. Yung S., Chau M.K., Zhang Q., et al. Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin-induced type I diabetic nephropathy. PLoS One. 2013;8(1):e54501.

46. Masola V., Onisto M., Zaza G., et al. A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. J Transl Med. 2012;10:213. Doi: 10.1186/1479-5876-10-213.

47. Cha J.J., Kang Y.S., Hyun Y.Y., et al. Sulodexide improves renal function through reduction of vascular endothelial growth factor in type 2 diabetic rats. Life Sci. 2013;92(23):1118–24. Doi: 10.1016/j.lfs.2013.04.008.

48. Kristova V., Liskova S., Sotnikova R., et al. Sulodexide improves endothelial dysfunction in streptozotocin-induced diabetes in rats. Physiol Res. 2008;57(3):491–94. Doi: 10.33549/physiolres.931506.

49. Coccheri S., Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Devel Ther. 2014;8:49–65. Doi: 10.2147/DDDT.S6762

50. Lambers Heerspink H.J., Fowler M.J., Volgi J., et al. Collaborative Study Group Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy. Diabet Med. 2007;24(11):1290–95. Doi: 10.1111/j.1464-5491.2007.02249.x.

51. Bu H., Xu K., Zhang H. The effect of sulodexide on the diabetic nephropathy. Journal of Henan Medical College for Staff and Workers. 2012;24(2):146–47.

52. Liu S. Therapeutic effects of sulodexide combined with benazapril on patients with diabetic kidney disease. Chin J Diffic and Compl Cas. 2011;10:21–2.

53. Xiong Y. Treatment of sulodexide on albuminuria in early diabetic nephropathy. J Jianghan Univ (Nat Sci Ed) 2014;42:90–2.